Literature DB >> 20673820

Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.

Stéphanie Pannier1, Emilie Mugniery, Aurélie Jonquoy, Catherine Benoist-Lasselin, Thierry Odent, Jean-Philippe Jais, Arnold Munnich, Laurence Legeai-Mallet.   

Abstract

Achondroplasia (ACH), the most common form of human dwarfism is caused by a mutation in the Fibroblast Growth Factor Receptor 3 (FGFR3) gene, resulting in constitutive activation of the receptor. Typical radiological features include shortening of the tubular bones and macrocephaly, due to disruption of endochondral ossification. Consequently, FGFR3 has been described as a negative regulator of bone growth. Studying a large cohort of ACH patients, a delay in bone age was observed shortly after birth (for boys p=2.6×10(-9) and for girls p=1.2×10(-8)). This delay was no longer apparent during adolescence. In order to gain further insight into bone formation, bone development was studied in a murine model of chondrodysplasia (Fgfr3(Y367C/+)) from birth to 6weeks of age. Delayed bone age was also observed in Fgfr3(Y367C/+) mice at 1week of age followed by an accelerated secondary ossification center formation. A low level of chondrocyte proliferation was observed in the normal growth plate at birth, which increased with bone growth. In the pathological condition, a significantly high level of proliferative cells was present at birth, but exhibited a transient decrease only to rise again subsequently. Histological and in situ analyses suggested the altered endochondral ossification process may result from delayed chondrocyte differentiation, disruption of vascularization and osteoblast invasion of the femur. All these data provide evidence that FGFR3 regulates normal chondrocyte proliferation and differentiation during bone growth and suggest that constitutive activation of the receptor disrupts both processes. Therefore, the consequences of FGFR3 activation on the physiological process of bone development appear to be dependent on spatial and temporal occurrence. In conclusion, these observations support the notion that FGFR3 has a dual effect, as both a negative and a positive regulator of the endochondral ossification process during post-natal bone development.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673820     DOI: 10.1016/j.bone.2010.07.020

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  11 in total

1.  Bone: FGFR3 mutation delays bone age in achondroplasia.

Authors:  Linda Koch
Journal:  Nat Rev Endocrinol       Date:  2010-11       Impact factor: 43.330

Review 2.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

3.  Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating chondrocytes.

Authors:  Zi-Qiang Zhou; Sara Ota; Chuxia Deng; Haruhiko Akiyama; Peter J Hurlin
Journal:  Hum Mol Genet       Date:  2014-11-28       Impact factor: 6.150

4.  Phosphate regulates chondrogenesis in a biphasic and maturation-dependent manner.

Authors:  Biming Wu; Emily K Durisin; Joseph T Decker; Evran E Ural; Lonnie D Shea; Rhima M Coleman
Journal:  Differentiation       Date:  2017-05-08       Impact factor: 3.880

5.  Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.

Authors:  Davide Komla-Ebri; Emilie Dambroise; Ina Kramer; Catherine Benoist-Lasselin; Nabil Kaci; Cindy Le Gall; Ludovic Martin; Patricia Busca; Florent Barbault; Diana Graus-Porta; Arnold Munnich; Michaela Kneissel; Federico Di Rocco; Martin Biosse-Duplan; Laurence Legeai-Mallet
Journal:  J Clin Invest       Date:  2016-04-11       Impact factor: 14.808

6.  Prevention of guanylyl cyclase-B dephosphorylation rescues achondroplastic dwarfism.

Authors:  Brandon M Wagner; Jerid W Robinson; Yun-Wen Lin; Yi-Ching Lee; Nabil Kaci; Laurence Legeai-Mallet; Lincoln R Potter
Journal:  JCI Insight       Date:  2021-05-10

7.  Concomitant achondroplasia and developmental dysplasia of the hip.

Authors:  Tennison L Malcolm; Duy L Phan; Ran Schwarzkopf
Journal:  Arthroplast Today       Date:  2015-11-18

8.  Skeletal Characterization of the Fgfr3 Mouse Model of Achondroplasia Using Micro-CT and MRI Volumetric Imaging.

Authors:  Mohammed Salman Shazeeb; Megan K Cox; Anurag Gupta; Wen Tang; Kuldeep Singh; Cynthia T Pryce; Robert Fogle; Ying Mu; William D Weber; Dinesh S Bangari; Xiaoyou Ying; Yves Sabbagh
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

9.  Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth.

Authors:  Leia C Shuhaibar; Nabil Kaci; Jeremy R Egbert; Thibault Horville; Léa Loisay; Giulia Vigone; Tracy F Uliasz; Emilie Dambroise; Mark R Swingle; Richard E Honkanen; Martin Biosse Duplan; Laurinda A Jaffe; Laurence Legeai-Mallet
Journal:  JCI Insight       Date:  2021-05-10

10.  Meckel's and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible.

Authors:  Martin Biosse Duplan; Davide Komla-Ebri; Yann Heuzé; Valentin Estibals; Emilie Gaudas; Nabil Kaci; Catherine Benoist-Lasselin; Michel Zerah; Ina Kramer; Michaela Kneissel; Diana Grauss Porta; Federico Di Rocco; Laurence Legeai-Mallet
Journal:  Hum Mol Genet       Date:  2016-06-03       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.